Strategies for prostate cancer prevention: Review of the literature
PMC2684344 : The goal of primary chemoprevention is to decrease the incidence of a given cancer, simultaneously reducing treatment-related adverse events, cost of treatment of the disease and mortality.
Prostate cancer is an attractive and appropriate target for primary prevention because of its high incidence and prevalence, increased disease-related mortality, long latency and molecular pathogenesis and epidemiological data indicating that modifiable environmental factors may decrease risk.
Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation
PMC3925258 : Dietary phytochemicals offer non-toxic therapeutic management as well as chemopreventive intervention for slow-growing prostate cancers.
Here we show antiproliferative efficacy of the mostactive GE biophenolics as single-agents and in binary combinations, and investigate the nature of their interactions using the Chou-Talalay combination-index (CI) method.
Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells
PMC2241638 : Ginger (Zingiber officinale Rosc) is a natural dietary component with antioxidant and anticarcinogenic properties. The ginger component -gingerol has been shown to exert antiinflammatory effects through mediation of NF-κB. NF-κB can be constitutively activated in epithelial ovarian cancer cells and may contribute towards increased transcription and translation of angiogenic factors. In the present study, we investigated the effect of ginger on tumor cell growth and modulation of angiogenic factors in ovarian cancer cells in vitro.
PMC3348998 : The role of lipid metabolism has gained particular interest in prostate cancer research. A large body of literature has outlined the unique upregulation of de novo lipid synthesis in prostate cancer. Concordant with this lipogenic phenotype is a metabolic shift, in which cancer cells use alternative enzymes and pathways to facilitate the production of fatty acids.
Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem
PMC3734867 : Early detection is the key to effective treatment of prostate cancer, and to the prevention of deaths due to progression to untreatable advanced stage cancer. Because of mitigating factors, especially benign prostatic hyperplasia (BPH), that result in a low accuracy (about 60%) of prostate-specific antigen (PSA) testing, there is an urgent need for a more reliable biomarker for the identification of early stage through advanced stage prostate cancer and ‘at-risk’ individuals.
Recent developments in prostate cancer biomarker research: therapeutic implications
PMC3040536 : Rapid increases in incidence rates for prostate cancer in the past two decades have occurred in part due to the widespread use of screening since the 1980s, by serum prostate-speciﬁc antigen (PSA), a glycoprotein produced
by the prostate gland.
Tissue Biomarkers for Prostate Cancer Radiation Therapy
PMC3412203 : : Prostate cancer is the most common cancer and second leading cause of cancer deaths among men in the United States. Most men have localized disease diagnosed following an elevated serum prostate specific antigen test for cancer screening purposes. Standard treatment options consist of surgery or definitive radiation therapy directed by clinical factors that are organized into risk stratification groups.